2003, DNA and Drug Development - Drug Discovery Digest

New understanding of the TMEJ pathway in cancer

Drug Target Review

DECEMBER 14, 2023

Throughout the course of our lives, natural and environmental factors can break DNA. Breaks in both DNA strands are a particularly dangerous threat to genome stability. At a DNA double-strand break (DSB), potentially lost sequence information cannot be recovered from the same DNA molecule.

DNA

DNA Clinical Trials Treatment Research

New Drug Miplyffa Approved for Rare Niemann-Pick Disease Type 3

PLOS: DNA Science

OCTOBER 17, 2024

The first-ever approval of a safe and effective drug option will undoubtedly support the essential medical needs of those suffering.” ” Miplyffa is the first drug developed to treat NPD3 specifically. The new drug is taken with miglustat , which FDA approved for use in NPD3 in 2009.

Disease

Disease FDA Approval Drugs Treatment

Drug Discovery Digest

New understanding of the TMEJ pathway in cancer

New Drug Miplyffa Approved for Rare Niemann-Pick Disease Type 3

Webinars

Stay Connected